Amino acid peptide for spinal pain relief

Spine BioPharma is dedicated to developing innovative, non-surgical, and non-opiate therapies aimed at treating degenerative spine-related diseases. Their primary focus is on SB-01, a first-in-class therapeutic candidate designed specifically for degenerative disc disease. This treatment is administered via intradiscal injection by a physician and is intended to provide significant clinical benefits, including pain relief, restoration of function, and the potential to halt or slow disease progression. The company emphasizes its commitment to improving the quality of life for individuals suffering from chronic low back pain and other spine-related conditions.

The company’s approach is rooted in solid scientific research and clinical experience, with a mission to deliver safe and effective therapies that address pain and inflammation associated with degenerative spine diseases. Spine BioPharma collaborates with pharmaceutical companies, scientists, and clinicians to develop a portfolio of therapeutic solutions that are expected to be first-in-class or best-in-class treatments. Their ongoing efforts include navigating the regulatory approval processes to ensure that these innovative therapies become accessible to millions of patients in need.

United States

Patients around the world are struggling with debilitating back pain, trying to avoid invasive surgeries and the potential of opioid addiction. Spine Biopharma has developed a non-surgical solution that will remove pain and restore functionality, without having to use opioids.


Spine BioPharma

Company Details